Dr. Pilotto is a medical oncologist, assistant professor at the University of Verona. She completed her graduate studies and residency in medical oncology with full marks and honors at the University Hospital Trust of Verona (Italy) and she trained in the Translational Research Unit at the Pangaea Biotech laboratory, Quiron-Dexeus University Hospital, Barcelona (Spain) thanks to a fellowship award of the International Association for Lung Cancer (IASLC) in 2015. In 2019, she completed her PhD in Inflammation, Immunity and Cancer at the University of Verona (Italy).
Dr. Pilotto is member of the Young investigators Lung Cancer Group of EORTC, of the Lung cancer Guidelines Experts Panel of Italian Association of Medical Oncology (AIOM) and member of the ESMO faculty for the Non-Metastatic NSCLC and other Thoracic Malignancies faculty group and of the ESMO Press & Media Affairs Committee. She was reviewer for the Projects and/or Research Grants for IASLC (2017-2019) and member of the ESMO leadership program 2019.
Main Research/Clinical Interest Areas: clinical and translational research in lung cancer; prognostic and predictive models; methodology of clinical trials; comprehensive approach to cancer patient (i.e. nutrition, physical activity).

Silvia Novello, MD, PhD is Full Professor of Medical Oncology in the Oncology Department at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. She earned her medical degree and completed the postgraduate training in Respiratory Medicine and Medical Oncology at the University of Turin and partially at the Institut Gustave Roussy, in France. Currently, she is head of the Thoracic Oncology Unit at the San Luigi Hospital, Orbassano (Turin), where she also tutors medical students and Postgraduate students in Respiratory Medicine and Medical Oncology and Deputy Director of the Oncology Dept.

Prof. Novello’s research interests include thoracic malignancies, primary prevention, gender differences in lung cancer, basic, translational and clinical applied research on lung cancer and mesothelioma, including pharmacogenomics. She is involved as PI in many International and national controlled clinical trials evaluating new approaches in diagnosis and lung cancer therapy.

From July 2012 until 2016, Prof Novello has been a Member of the Board of Directors of the International Association for the Study of Lung Cancer and since October 2016 Member of the Board of Directors of the Italian Association of Medical Oncology, past Secretary and now part of the EORTC Lung Cancer Group and member of several scientific societies including the American Society of Clinical Oncology, American Thoracic Society and the European Society of Medical Oncology.
Currently, she is the President of WALCE (Women Against Lung Cancer in Europe), a non profit European Association founded in 2006 in Turin, Italy, part of the scientific Committee of LuCe (Lung cancer Europe) and also member of the Scientific Committee of Bonnie J Addario Lung Cancer Foundation and Member of the Scientific Committee of ICAPEM (Investigación sobre Cáncer de Pulmón en Mujeres).

She is the author or co-author of over 150 publications in peer-reviewed journals.

Giorgio Scagliotti is a Full Professor of Medical Oncology. He was Chief of the Department of Oncology at the University of Turin until September 2017 and now he is member of the Administrative Board of the University of Turin, Italy, and Chief of the Medical Oncology Unit at the S. Luigi Hospital, Orbassano (Turin). He earned his medical degree and completed postgraduate training in Respiratory medicine, Internal medicine, and Medical oncology at the University of Turin. His research interests include basic and clinical research in lung cancer, including pharmacogenomics. He is affiliated to several scientific societies and he has authored and co - authored over 300 publications.
He is coordinator of national, European and international clinical trials on the diagnosis and treatment of lung cancer.
He was President IASLC (International Association for the Study of Lung Cancer) for the period 2017-2019 and he is now Interim CSO.